Lipitor, i.e. Paclitaxel Liposome for Injection, Paclitaxel Liposome for Injection and Carboplatin are combination chemotherapy drugs for the treatment of non-small cell lung cancer, and the efficacy of chemotherapy is relatively good in clinic, but the specific effective rate is related to the stage of the cancer and one’s own condition. Lung cancer is one of the more common cancers, of which non-small cell lung cancer accounts for up to 75%~80% of lung cancer. According to the literature research, in the advanced stage of non-small cell lung cancer, the effective rate of combined chemotherapy of paclitaxel liposome and carboplatin can be up to 52.4%, and the effective rate is even higher in the early and middle stage, and at present, the combination of paclitaxel liposome and carboplatin is the first-line therapy for non-small cell lung cancer that can not be treated by surgery. As a new type of anticancer drug, paclitaxel liposome for injection, its active ingredient paclitaxel can be encapsulated by lecithin, so as to reduce the occurrence of gastrointestinal reactions, allergies and other adverse reactions. And carboplatin may have neurotoxicity, nephrotoxicity and other adverse reactions during the use of the drug. It is recommended to take reasonable medication under the guidance of a doctor to avoid the occurrence of serious adverse reactions after the use of the drug.